High‐dose intravenous immunoglobulin (IVIg) is commonly used during kidney transplantation. Its nephrotoxicity has been attributed to sucrose stabilizers. We evaluated the renal safety of newer formulations of sucrose‐free IVIg. We retrospectively studied clinical and histological data from 75 kidney recipients receiving high‐dose, sucrose‐free IVIg courses. This group was compared with 75 matched kidney recipients not treated with IVIg. Sucrose‐free IVIg treatment was not associated with any acute kidney injury episode at 3 months, but an increased frequency of tubular macrovacuoles (28% vs. 2.8%, P < 0.001) was observed. Among IVIg‐treated patients, the presence of macrovacuoles at 3 months was associated with increased IF/TA scores at 3 months (1.7 ± 1 vs. 1 ± 1, P = 0.005) and was more often observed in kidneys with higher IF/TA scores on day 0 (0.6 ± 0.9 vs. 0.3 ± 0.8, P = 0.03) at 3 months. Finally, patients treated with amino‐acid‐stabilized formulations developed fewer macrovacuoles at 3 months (12% vs. 60%; P < 0.001) than those treated with carbohydrate‐stabilized IVIg. Our study shows that high‐dose, sucrose‐free IVIg use in early kidney recipients is clinically well tolerated. Among sucrose‐free IVIg, amino‐acid‐stabilized formulations are associated with less tubular toxicity than carbohydrate‐stabilized IVIg.